NAMS NewAmsterdam Pharma Company N.V.
$20.93+5.18%
Last close: · regular session · Last 60 sessions
After-hours $20.86 -0.33% ·
- Float
- 86.2M
- Last filing
- 8-K · Sep 29, 2026
Latest SEC filings for NAMS
| 8-K | Current report | |
| 8-K | Current report | |
| 8-K/A | Current report | |
| 8-K | Current report | |
| 10-Q | Quarterly report | |
| 8-K | Current report | |
| 8-K | Current report | |
| 8-K | Current report | |
| 8-K | Current report | |
| 8-K | Current report |
Dilution today: new offering filings and reverse splits
Float: 86.2M shares. Latest SEC filing: 8-K on Sep 29, 2026. NAMS closed at $20.93 (+5.18%) on Nov 4, 2026.
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for NAMS in the TickerWise workspace.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: NL
- Exchange: NASDAQ
- Employees: 68
- Website: https://www.newamsterdampharma.com
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.
Latest NAMS news
- NewAmsterdam Pharma GAAP EPS of -$0.14 beats by $0.30, revenue of $19.16M beats by $4.11M Read article
Recent dilution filers
Related companies
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.